Premium
Renal cancer staging: Comparison of contrast‐enhanced CT and gadolinium‐enhanced fat‐suppressed spin‐echo and gradient‐echo MR imaging
Author(s) -
Semelka Richard C.,
Patrick Shoenut J.,
Magro Cynthia M.,
Kroeker Mervyn A.,
Macmahon Ross,
Greenberg Howard M.
Publication year - 1993
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880030408
Subject(s) - medicine , magnetic resonance imaging , radiology , nuclear medicine , gadolinium , tomography , biopsy , metallurgy , materials science
Abstract Fifty‐three consecutive patients with 61 solid or complex non‐fat‐containing renal masses compatible with renal cancer were examined with contrast‐enhanced computed tomography (CT) and magnetic resonance (MR) imaging with pre‐ and postcontrast FLASH (fast low‐angle shot) and fat‐suppressed spin‐echo sequences. CT and MR imaging were performed within a 1‐month interval. CT and MR images were prospectively interpreted. Tumor detection and staging were determined in all patients. CT and MR imaging enabled detection of 54 and 58 of 61 renal tumors, respectively. CT and MR imaging showed 34 and 35 of 38 histologically proved renal tumors, respectively, in 31 patients. Tumor size on CT and MR images demonstrated good correlation and correlated well with the size of pathologic specimens of 34 of 38 resected tumors detected with CT and MR imaging (r =.99). Of the 31 tumors in 31 patients who underwent surgical resection, 24 were correctly staged with CT and 29 with MR imaging. CT and MR imaging both enabled correct staging of four of five additional tumors with biopsy proof of tumor stage. A moderate difference in staging was observed between CT and MR imaging (P =.05). CT showed 13 and MR imaging 15 of 15 tumor thrombi. CT and MR imaging both showed 11 of 11 cases of adenopathy. The results suggest that MR imaging is moderately better than CT for the detection and staging of renal cancer.